课题基金 / 基金详情

Specialized Program Of Research Excellence (SPORE) in Leukemia.

Specialized Program Of Research Excellence (SPORE) in Leukemia.
白血病专业卓越研究计划 (SPORE)。
批准号:
10912197
负责人:
Daniel C Link
金额:
$91.86万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-03 至 2024-06-30
关键词:
AML/MDSAccreditationAcuteAcute Lymphocytic LeukemiaAcute Myelocytic LeukemiaAcute T Cell LeukemiaAcute leukemiaAddressAdoptive ImmunotherapyAdverse eventAdvocacyAgonistAllogenicAlternative SplicingAnimalsAntibody TherapyApplications GrantsAwardBasic ScienceBioinformaticsBiological AssayBiological AvailabilityBiological Specimen BanksBiologyBiometryBiostatistics CoreBispecific AntibodiesBloodBone MarrowBone Marrow AspirationBone Marrow CellsCRISPR screenCancer CenterCancer Control ResearchCancer Research ProjectCatalogsCell CountCell DeathCell LineCell TherapyCell modelCellsCellular biologyCharacteristicsChronic Myelomonocytic LeukemiaCitrusClinicClinicalClinical DataClinical ResearchClinical TrialsClinical Trials DesignCollaborationsCollectionCombined Modality TherapyCommunicationCommunitiesConsentConsultContractsCyclophosphamideCytometryCytoprotectionDNADNA DamageDNA Sequence AlterationDNA damage checkpointDataData AnalysesDatabasesDecitabineDevelopmentDevelopment PlansDiagnosisDisabled PersonsDiseaseDisease ProgressionDisease remissionDisease-Free SurvivalDisparityDocumentationDoseDrug CombinationsDysmyelopoietic SyndromesEarly DiagnosisEducationEducational StatusEducational workshopEffectivenessElectronicsEngraftmentEnrollmentEnsureEnvironmentEquipment and supply inventoriesEquityErythropoietinEthicsEtiologyEvaluable DiseaseExclusionExhibitsFacultyFamilyFeedbackFemaleFinancial SupportFosteringFundingFutureGenesGeneticGenetically Engineered MouseGenomeGenomic InstabilityGenomicsGoalsGrantGrant ReviewGroup MeetingsGuidelinesHaptensHealth Insurance Portability and Accountability ActHematologic NeoplasmsHematopoiesisHematopoieticHumanHybridsImmuneImmune systemImmunologyImmunotherapyIn VitroIncidenceIndividualInfrastructureInstitutionInstitutional Review BoardsInterleukin-15InvestigationJointsJournalsLaboratoriesLeadershipLeukemic CellLicensingLigandsLinkLongevityMalignant NeoplasmsManuscriptsMeasuresMediatingMemoryMentorsMethodsMinorityMinority ParticipationMinority RecruitmentMissionModelingMolecularMonitorMulti-Institutional Clinical TrialMultiple MyelomaMutateMutationMyeloproliferative diseaseNK cell therapyNatural Killer Cell ImmunotherapyNatural Killer CellsNatural SelectionsNewly DiagnosedNewsletterNucleic AcidsOperative Surgical ProceduresOralOutcomeOutputParticipantPathogenesisPatient CarePatientsPeer ReviewPhasePhase I/II TrialPhenotypePhysiciansPilot ProjectsPopulationPopulation SciencesPostbaccalaureatePre-Clinical ModelPreparationPreventionProcessProfessional CompetencePrognosisPrognostic FactorProgram EvaluationProgram ReviewsProgress ReportsProgression-Free SurvivalsPropertyProtocols documentationPubMedPublicationsPublishingQualifyingQuality ControlRNARNA SplicingReceptor CellRecommendationRecurrenceRecurrent diseaseRefractoryRegimenRegulatory T-LymphocyteRelapseReportingResearchResearch DesignResearch PersonnelResearch Project GrantsResearch TrainingResidual stateResistanceResolutionResource SharingResourcesRiskRunningSRSF2 geneSafetySalvage TherapySamplingScienceSerumServicesSignal PathwaySignal TransductionSingle-Stranded DNASkinSpecialized Program of Research ExcellenceSpecificitySpecimenSpliceosomesStatistical MethodsStructureStudentsT-LymphocyteTalentsTestingTherapeuticTherapeutic TrialsTimeTissue ProcurementsTissuesToxic effectTrainingTraining ProgramsTransfusionTranslatingTranslational ResearchTravelUnited States National Institutes of HealthUniversitiesVirus DiseasesVisitWagesWashingtonWomanWorkWritinganticancer researchbiobankbiomarker identificationcancer genomicscancer health disparitycancer preventioncareercareer developmentcell typechronic graft versus host diseasechronic leukemiaclinical databaseclinical developmentconditioningcostcytokinedata sharingdesignefficacy testingepidemiologic dataepidemiology studyexome sequencingexperienceexperimental studyfirst-in-humanfunctional statusfundamental researchgenome-widegraft vs host diseasegraft vs leukemia effecthematopoietic cell transplantationhigh riskhuman studyimprovedin vivoinformatics toolinhibitorinnovationlaboratory experimentleukemialeukemia relapseleukemia treatmentmeetingsmembermid-career facultyminority investigatormortalitymouse modelmultidimensional datamutantnovelnovel markernovel therapeutic interventionnovel therapeuticsolder patientoperationoutreachpatient orientedpeerpharmacologicphase 2 studyphase II trialpre-clinicalpreclinical studypreservationprimary endpointprogramsprospectiverecruitresearch and developmentresearch studyresponseresponse biomarkersecondary endpointskill acquisitionsmall moleculestandard carestandard of caresuccesstargeted treatmenttooltranscriptome sequencingtranslational approachtranslational cancer researchtranslational clinical trialtumorweb-based tool

项目摘要

项目成果

Daniel C Link的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT The Washington University SPORE in Leukemia is a highly dynamic translational cancer research program that focuses specifically on leukemias and myelodysplastic syndromes (MDS). We have assembled an outstanding group of investigators with complementary expertise in basic and clinical leukemia research. In this SPORE, we leverage expertise in cancer genomics, immunology, and hematopoiesis to develop innovative translational research in leukemia. Our long-term goal is to develop novel biomarkers and treatments for leukemias and myelodysplastic syndromes and to develop and promote innovative translational leukemia research. To achieve these goals, the following specific aims are proposed. Aim 1. We will exploit institutional expertise in cancer genomics, immunology, and hematopoiesis to develop novel biomarkers and treatments for leukemias and myelodysplastic syndromes. Basic research at WUSM has led to the development of the following five translational research projects, all featuring innovative investigator-initiated therapeutic trials for leukemias or MDS. · Project 1. Molecular determinants of decitabine responsiveness · Project 2. Targeted therapies for T cell acute lymphoblastic leukemia (T-ALL) · Project 3. Novel therapies for splicesome-mutant MDS · Project 4. Bi-specific antibody-based therapies for AML · Project 5. Memory-like NK cell augmented hematopoietic cell transplantation for AML Aim 2. We will enhance the infrastructure that supports translational leukemia research. This SPORE will support the following Shared Research Resources: 1) Core A. Biospecimen Processing; 2) Core B. Biostatistics; and 3) Core C. Administration. Aim 3. We will recruit and train new investigators in translational research. This SPORE will support a Career Enhancement Program (CEP) to recruit and mentor new investigators in translational leukemia research. The SPORE has established a successful minority post-baccalaureate training program. The SPORE also will support a Developmental Research Program (DRP) to support innovative translational concepts. Aim 4. We will facilitate inter-SPORE collaboration. Four of the SPORE projects include multi-institutional clinical trials, including three at other Leukemia SPORE institutions. We have established CEP educational exchange and grant review programs with peer Leukemia SPORE institutions. We will continue to organize and participate in joint meetings of Leukemia SPOREs at MD Anderson and Harvard.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1182/blood-2016-10-692400
发表时间: 2017-03
期刊: Blood
影响因子: 20.3
作者: [B. Saez;M. Walter;T. Graubert]
通讯作者: B. Saez;M. Walter;T. Graubert
DOI: 10.1016/j.leukres.2016.07.010
发表时间: 2016-10
期刊: LEUKEMIA RESEARCH
影响因子: 2.7
作者: [Ghobadi, Armin, Choi, Jaebok, Fiala, Mark A., Fletcher, Theresa, Liu, Jingxia, Eissenberg, Linda G., Abboud, Camille, Cashen, Amanda, Vij, Ravi, Schroeder, Mark A., Pusic, Iskra, Stockerl-Goldstein, Keith, Jacoby, Meagan, Uy, Geoffrey, DiPersio, John, Westervelt, Peter]
通讯作者: Westervelt, Peter
DOI: 10.1016/j.bbmt.2015.10.019
发表时间: 2016-04
期刊: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
影响因子: --
作者: [Rashidi A, Ebadi M, Colditz GA, DiPersio JF]
通讯作者: DiPersio JF
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
鲁索替尼对患者亚组的临床益处:对骨髓纤维化患者的安慰剂对照 III 期研究进行分析。
DOI: 10.1111/bjh.12274
发表时间: 2013
期刊: British journal of haematology
影响因子: 6.5
作者: [Verstovsek,Srdan, Mesa,RubenA, Gotlib,Jason, Levy,RichardS, Gupta,Vikas, DiPersio,JohnF, Catalano,JohnV, Deininger,Michael, Miller,Carole, Silver,RichardT, Talpaz,Moshe, Winton,ElliottF, HarveyJr,JimmieH, Arcasoy,MuratO, Hexner,Eli]
通讯作者: Hexner,Eli
11
    Identification of new genetic causes of congenital neutropenia
    • 批准号:
      10621903
    • 项目类别:
    • 资助金额:
      $39.38万
    • 财政年份:
      2020
    • 负责人:
      Daniel C Link
    • 依托单位:
    Identification of new genetic causes of congenital neutropenia
    • 批准号:
      10159977
    • 项目类别:
    • 资助金额:
      $39.38万
    • 财政年份:
      2020
    • 负责人:
      Daniel C Link
    • 依托单位:
    Identification of new genetic causes of congenital neutropenia
    • 批准号:
      10399626
    • 项目类别:
    • 资助金额:
      $39.38万
    • 财政年份:
      2020
    • 负责人:
      Daniel C Link
    • 依托单位:
    Single Cell Spatial Characterization of the Human Bone Marrow Microenvironment
    • 批准号:
      10115110
    • 项目类别:
    • 资助金额:
      $19.69万
    • 财政年份:
      2020
    • 负责人:
      Daniel C Link
    • 依托单位:
    海外基金